MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome

Conditions: Bariatric Surgery Candidate
Healthy
Obese

Interventions: Procedure: Endoscopic biopsy

First Posted Date: 2022-06-07

Last Posted Date: 2024-08-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 52

Registration Number: NCT05408728

Locations: 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

Targeting Inflammation for Endometrial Cancer Prevention

Active, not recruiting

Conditions: Endometrial Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2022-06-07

Last Posted Date: 2024-02-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 191

Registration Number: NCT05407025

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Phase 3

Withdrawn

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Drug: Olanzapine
Other: Questionnaire Administration
Drug: Placebo Administration

First Posted Date: 2022-06-03

Last Posted Date: 2024-05-06

Lead Sponsor: Mayo Clinic

Registration Number: NCT05403580

Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

Active, not recruiting

Conditions: Bladder Carcinoma

First Posted Date: 2022-06-01

Last Posted Date: 2024-02-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 34

Registration Number: NCT05399004

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Phase 3

Recruiting

Conditions: Radial Artery Occlusion

Interventions: Drug: Rivaroxaban

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 700

Registration Number: NCT05399277

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe

Not Applicable

Completed

Conditions: Lung Diseases, Obstructive
Lesions Mass
Bronchi--Diseases

Interventions: Device: Cryoprobe biopsy
Procedure: Forceps biopsy

First Posted Date: 2022-06-01

Last Posted Date: 2024-10-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT05399082

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

In-person Focus Groups in the Management of Urinary Incontinence in Women

Completed

Conditions: Urinary Incontinence

First Posted Date: 2022-05-27

Last Posted Date: 2023-05-06

Lead Sponsor: Mayo Clinic

Target Recruit Count: 10

Registration Number: NCT05395793

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, the Sofusa-2 Study

Phase 1

Active, not recruiting

Conditions: Clinical Stage III Cutaneous Melanoma AJCC V8
Melanoma
Metastatic Melanoma
Recurrent Metastatic Melanoma

Interventions: Biological: Anti-PD-L1 Monoclonal Antibody IMC-001
Procedure: Punch Biopsy

First Posted Date: 2022-05-26

Last Posted Date: 2024-12-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 3

Registration Number: NCT05393713

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Phase 1

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Biological: Daratumumab
Drug: Dexamethasone
Drug: Iberdomide

First Posted Date: 2022-05-26

Last Posted Date: 2024-12-24

Lead Sponsor: Mayo Clinic

Target Recruit Count: 18

Registration Number: NCT05392946

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Phase 2

Completed

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Malignant Solid Neoplasm

Interventions: Drug: Cannabidiol
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-05-24

Last Posted Date: 2024-04-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT05388058

Locations: 🇺🇸
Fairview Range Medical Center, Hibbing, Minnesota, United States
🇺🇸
Mayo Clinic Health System Albert Lea, Albert Lea, Minnesota, United States
🇺🇸
Mayo Clinic Health System Mankato, Mankato, Minnesota, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy